Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Friday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Up 1.7 %

ADXS stock opened at $0.03 on Friday. The firm’s 50-day moving average price is $0.03 and its two-hundred day moving average price is $0.03. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.98. The stock has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.63.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.